Palliative radiotherapy

RADIATION20 trials

Sponsors

National University Hospital, Singapore, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Royal Marsden NHS Foundation Trust, Melanoma and Skin Cancer Trials Limited, Dana-Farber Cancer Institute

Conditions

Bladder CancerCancerCervical CancerEsophageal Squamous Cell CarcinomaGastric CancerGastrointestinal AdenocarcinomaGastrointestinal CancerGastrointestinal Squamous Cell Cancer

Phase 1

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

Royal Marsden NHS Foundation TrustSolid Tumour Refractory to Conventional Treatment

Start: 2014-07-31End: 2025-12-30Target: 87Updated: 2025-08-01

Radiotherapy & Combi in Metastatic Melanoma

CompletedNCT02392871

Melanoma and Skin Cancer Trials LimitedMetastatic Melanoma

Start: 2015-05-31End: 2020-04-17Updated: 2024-11-27

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

CompletedNCT05002140

XRad Therapeutics IncLocally Advanced Solid Tumor, Metastasis, Recurrent Cancer

Start: 2021-08-24End: 2023-07-21Updated: 2024-01-11

A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors

TerminatedNCT06524804

Chengdu Baiyu Pharmaceutical Co., Ltd.Solid Tumor, Adult

Start: 2024-05-15End: 2024-10-18Updated: 2024-12-18

Phase 2

Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial

National University Hospital, SingaporeGastric Cancer

Start: 2009-07-31End: 2012-07-31Target: 63Updated: 2011-05-09

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

Active, not recruitingNCT01446744

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sMetastatic Tumors

Start: 2011-11-30End: 2026-06-30Updated: 2023-10-05

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

TerminatedNCT03051672

Dana-Farber Cancer InstituteMetastatic Breast Cancer

Start: 2017-05-22End: 2019-01-11Updated: 2021-04-27

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Shanghai Chest HospitalEsophageal Squamous Cell Carcinoma

Start: 2019-05-22End: 2021-12-31Target: 100Updated: 2019-05-29

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

RecruitingNCT05010031

Memorial Sloan Kettering Cancer CenterMetastatic Cancer

Start: 2021-08-11End: 2027-08-01Target: 40Updated: 2026-01-23

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Not yet recruitingNCT07116577

Jinan Central HospitalmCRC

Start: 2025-08-31End: 2028-12-31Target: 37Updated: 2025-08-11

Phase 3

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

RecruitingNCT05717166

David PalmaMetastatic Tumor

Start: 2023-10-06End: 2029-04-30Target: 180Updated: 2025-12-31

Unknown Phase

Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer

Zealand University HospitalHormone-refractory Prostate Cancer

Start: 2018-08-01End: 2020-08-01Target: 34Updated: 2018-09-12

Prognosis of Patient Evaluated for Palliative Radiotherapy

Tuen Mun HospitalCancer, Radiotherapy

Start: 2019-01-01End: 2019-12-31Target: 450Updated: 2019-01-09

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Active, not recruitingNCT03862911

British Columbia Cancer AgencyMetastatic Tumors

Start: 2019-11-01End: 2030-12-31Target: 330Updated: 2025-11-28

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

RecruitingNCT05837767

Memorial Sloan Kettering Cancer CenterBladder Cancer, Gastrointestinal Adenocarcinoma, Gastrointestinal Cancer +12

Start: 2023-07-24End: 2026-07-24Target: 26Updated: 2026-03-30

Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

RecruitingNCT05947513

Addis Ababa UniversityCervical Cancer

Start: 2025-04-10End: 2026-04-30Target: 27Updated: 2025-04-20

Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors

RecruitingNCT06398314

Sykehuset TelemarkGastrointestinal Cancer, Gynecologic Cancer, Urologic Cancer

Start: 2024-12-10End: 2030-12-31Target: 200Updated: 2025-05-23

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

RecruitingNCT06529081

Copernicus Memorial HospitalSmall Cell Lung Carcinoma

Start: 2024-04-01End: 2029-12-31Target: 165Updated: 2025-08-28

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

RecruitingNCT06918951

British Columbia Cancer AgencyOligometastatic Disease, Oligoprogression, OligoProgressive Metastatic Disease

Start: 2025-12-04End: 2033-06-01Target: 194Updated: 2025-12-15

High Dose Radiotherapy for Palliation (Hi-D)

Not yet recruitingNCT07291895

British Columbia Cancer AgencyMetastases, Palliative Radiotherapy

Start: 2026-01-01End: 2029-08-31Target: 20Updated: 2025-12-18

Related Papers

Palliative radiotherapy in symptomatic pelvic soft tissue tumors (PallSoft)– protocol for a national, randomized, non-inferiority study

BMC Cancer2025-07-01

Radiotherapy integration strategy for small-cell lung cancer in extensive stage (RISE) with up to 10 metastases: A study protocol of a randomized phase II trial.

Journal of Clinical Oncology2025-05-28

World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.

Journal of Clinical Oncology2025-02-1016 citations

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial

BMC Cancer2025-01-244 citations

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

BMC Palliative Care2024-09-0710 citations

A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors

Molecular Cancer Therapeutics2024-04-0820 citations

Abstract LB181: First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors

Cancer Research2024-04-052 citations

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Journal of Clinical Investigation2023-11-0736 citations

Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

Cancer Research2020-08-15

Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.

2020-05-0586 citations

A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).

Journal of Clinical Oncology2019-05-204 citations

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

2019-04-111292 citations

Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO).

2019-01-101 citations

Abstract OT1-02-02: A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancer

Cancer Research2018-02-151 citations

Identifying barriers to accrual in radiation oncology randomized trials.

2017-12-2012 citations

Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)

Cancer Research2017-07-0136 citations

Patient reported outcomes following palliative gastric RadiOtherapy for symptomatic advanced gastric cancer (PROG): Results from a phase 2 trial.

Journal of Clinical Oncology2017-05-20

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Journal of Clinical Oncology2016-05-2011 citations